Skip to main content
OpenTrials
Completed

NCT Number: NCT05046015

Comparison Dry Foot Skin Between Diabetic and Non-diabetic Subjects and the Effects of Two Cosmetic Foot Care Products

The overall aims of this study are to compare the structure and function of dry to very dry and cracked foot skin between diabetic and nondiabetic subjects and to evaluate the effects of two cosmetic leave-on products on dry and fissured diabetic foot skin.

Specific issues are:

Are there any differences between the morphological and functional characteristics of dry to very dry and cracked skin foot between diabetic and nondiabetic subjects? What are the effects of a 4-week once daily application of an intensive care foot ointment (urea 10% foot ointment) or foot lotion (10% Urea foot lotion) on the skin barrier and on clinical signs of dryness and fissures?

Completed

Looking for future studies?

Notify Me

Key information

Age range

40 year–75 year

Sex eligibility

All sexes

Study type

Interventional

Phase

Not applicable

Primary location

Charité Universitatsmedizin Berlin

Berlin, Germany

About this study

A long existing diabetes mellitus type II is often associated with a number of skin changes. Xerosis Cutis is the most common skin alteration. The risk of diabetics of developing a foot ulcer is estimated to be 15%. Very dry and cracked skin represents an additional risk factor, so that adequate skin care is a widely recommended intervention in diabetic patients. But there are only few studies investigating the skin barrier structure and function in diabetic patients. Available study results seem to suggest, that for instance sebum content, stratum corneum hydration, and pH are associated with Diabetes mellitus.

The overall aims of this study are to compare the structure and function of dry to very dry and cracked foot skin between diabetic and nondiabetic subjects and to evaluate the effects of two cosmetic leave-on products on dry and fissured diabetic foot skin.

Specific issues are:

Are there any differences between the morphological and functional characteristics of dry to very dry and cracked skin foot between diabetic and nondiabetic subjects? What are the effects of a 4-week once daily application of an intensive care foot ointment (urea 10% foot ointment) or foot lotion (10% Urea foot lotion) on the skin barrier and on clinical signs of dryness and fissures?

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

diabetics and non-diabetics

  • Age 40 to 75 years
  • Moderate (categories 3 and 4), severe (category 5) dry skin according to the classification of Rogers et al. 1989
  • Degree of dryness comparable on both feet (maximum 1 category difference)
  • BMI between 18.5 and 34.9 kg/m2 (normal weight to class I obesity)
  • Able to understand and comply with the study requirements
  • additionally only for diabetics: Diabetes mellitus type 2 for at least 3 years according to Patient

Exclusion criteria

  • diabetics and non-diabetics
  • Any kind of adverse foot condition except xerosis like nail injury, ulceration, (suspected) infection including fungal infection
  • History of adverse foot condition except xerosis and tinea pedis, like nail injury, ulceration, pain
  • Mild xerosis cutis of feet (categories 1 and 2 according to Rogers et al. 1989)
  • Severe xerosis cutis of feet (category 6 according to Rogers et al. 1989)
  • Gait problems
  • Other non-controlled chronic and/or acute skin disease except xerosis (e.g. atopic dermatitis, psoriasis, tinea pedis)
  • Unstable chronic systemic disease (e.g. hypertension, renal insufficiency)
  • Acute systemic disease (e.g. infection)
  • Body temperature > 38°C
  • Pain anywhere
  • Wear of compression stockings at any time
  • Use of topical steroids
  • Use of skin care leave-on products on the feet in the previous 2 weeks
  • Known hypersensitivity or allergy to product ingredients
  • Drugs that might affect sweating (oral corticosteroids, psychoactive drugs)
  • Topical treatments other than the study products on the test areas within14 days prior Day 0 and during the course of the study
  • Pedicure/ medical foot care 14 days prior D 0 and during the course of the study
  • Any condition/ circumstance (e.g. cognitive impairment, visual impairment) that might interfere with study compliance in the opinion of the investigator
  • Current participation in another clinical study
  • Subject is institutionalized because of legal or regulatory order
  • additionally only for non-diabetics: Diabetes mellitus type 2 according to Patient
  • additionally only for diabetics:
  • Charcot osteoarthropathy
  • Neuropathy tested with a Semmes-Weinstein monofilament (according to Bakker et al. 2012)
  • Absence of pedal pulses (1) Posterior tibial artery (2) Dorsalis pedis artery

Treatment and study plan

10% Urea foot lotion

Other

During the course of the study participants cleanse one foot (previously randomized) once daily using the mild cleanser "Cetaphil® Restoraderm Body Wash" and apply the product "Excipial® U10 Lipolotion 10% Urea" once daily in the evening by themselves.

10% Urea foot ointment

Other

During the course of the study participants cleanse one foot (previously randomized) once daily using the mild cleanser "Cetaphil® Restoraderm Body Wash" and apply the product "Excipial® U10 ointment10% Urea" once daily in the evening by themselves.

Primary outcomes

  1. Change from Baseline in Overall Dry Skin Score

    Time frame: Baseline; Day 28±2

    Clinical assessment of the presence or severity of skin dryness using a 7 point scale at the sole of the foot (randomized). A score of '0' indicated normal skin/no sign of dryness, whereas a score of '6' indicates large-scale plates, deep erythematous fissures and cracks

Secondary outcomes

  1. Skin barrier

    Time frame: Day 0, Day 14±1,Day 28±2

    Transepidermal water loss: Measurement using the Tewameter®

    Three replicate measurements; according to the Technical Procedures G01_A1_V01 g/m2/h

Other outcomes

  1. Stratum corneum hydration

    Time frame: Day 28

    Stratum corneum hydration - Measurement using the Corneometer at Day 28

  2. Skin surface pH

    Time frame: Day 0 , Day 14, Day 28

    Skin surface pH

    Measurement using the pH-Meter® Three replicate measurements; according to the Technical Procedures G01_A4_V01

  3. Epidermal thickness

    Time frame: D28

    Epidermal thickness

    Measurement using OCT taking one image/ visit/ test area Mean of three epidermal thickness measurements; according to the Technical Procedures G04_A1_V01 μm

  4. Skin surface topography

    Time frame: Day 0, Day 28±2

    Skin surface topography - Measurement using Visioscan®

  5. Elasticity/Stiffness

    Time frame: Day 28

    Elasticity/Stiffness Measurement using Cutometer® at day 28

  6. lipids

    Time frame: Day 0, Day 28

    Oxidative stress on lipids Measurement according to sampling method of Synelvia (Version 2)

  7. Callus

    Time frame: Day 0, Day 28

    Callus

    • Clinical evaluation by study investigator
    • Classification of Callus severity according to Hashmi et al. 2015
  8. Cracks/ Fissures

    Time frame: Day 0, Day 28

    Cracks/ Fissures

    • Clinical evaluation by study investigator
    • Classification according to Oe et al. 2012

Sponsors and collaborators

Lead sponsor

Galderma R&D

Industry

Registry information

Official study title

Comparing Dry to Very Dry and Cracked Foot Skin Between Diabetic and Non-diabetic Subjects and the Effects of Two Cosmetic leave-on Foot Products: an Exploratory Study

Important dates

Study start
2016
Primary completion
2017
Study completion
2017
First posted
Sep 16, 2021
Registry last updated
Sep 16, 2021

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.